{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:58:11Z","timestamp":1761400691077,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T00:00:00Z","timestamp":1557532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pharmacogenetics Research Network Grant","award":["U-01 GM61373"],"award-info":[{"award-number":["U-01 GM61373"]}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fashion Footwear Charitable Foundation of New York\/QVC Presents Shoes on Sale \u2122"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10549-019-05270-4","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T14:58:38Z","timestamp":1557586718000},"page":"617-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy"],"prefix":"10.1007","volume":"176","author":[{"given":"Jennifer Y.","family":"Sheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghunandan","family":"Venkat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gedge","family":"Rosson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie C.","family":"Jeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Storniolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karineh","family":"Tarpinian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4018-4708","authenticated-orcid":false,"given":"Vered","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,11]]},"reference":[{"issue":"5","key":"5270_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2018","unstructured":"Burstein HJ et al (2018) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: aSCO clinical practice guideline focused update. J Clin Oncol 37(5):423\u2013438","journal-title":"J Clin Oncol"},{"issue":"9","key":"5270_CR2","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1200\/JCO.2011.38.0261","volume":"30","author":"NL Henry","year":"2012","unstructured":"Henry NL et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936\u2013942","journal-title":"J Clin Oncol"},{"issue":"4","key":"5270_CR3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2007.11.5451","volume":"26","author":"AH Partridge","year":"2008","unstructured":"Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556\u2013562","journal-title":"J Clin Oncol"},{"issue":"10001","key":"5270_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet 386(10001):1341\u20131352","journal-title":"The Lancet"},{"issue":"4","key":"5270_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1158\/1940-6207.CAPR-13-0389","volume":"7","author":"RT Chlebowski","year":"2014","unstructured":"Chlebowski RT, Kim J, Haque R (2014) Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev. Res. 7(4):378\u2013387","journal-title":"Cancer Prev. Res."},{"issue":"7","key":"5270_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","volume":"108","author":"B Makubate","year":"2013","unstructured":"Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515\u20131524","journal-title":"Br J Cancer"},{"issue":"3","key":"5270_CR7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ctrv.2007.10.004","volume":"34","author":"RE Coleman","year":"2008","unstructured":"Coleman RE et al (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275\u2013282","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"5270_CR8","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1200\/JOP.2012.000543","volume":"8","author":"EJ Aiello Bowles","year":"2012","unstructured":"Aiello Bowles EJ et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J. Oncol. Pract. 8(6):e149\u2013157","journal-title":"J. Oncol. Pract."},{"issue":"2","key":"5270_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/bcr2818","volume":"13","author":"S Gaillard","year":"2011","unstructured":"Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13(2):205","journal-title":"Breast Cancer Res"},{"issue":"21","key":"5270_CR10","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/JCO.2015.63.8619","volume":"34","author":"JH Chirgwin","year":"2016","unstructured":"Chirgwin JH et al (2016) Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of Tamoxifen and Letrozole, alone and in sequence. J Clin Oncol 34(21):2452\u20132459","journal-title":"J Clin Oncol"},{"issue":"2","key":"5270_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-007-9774-6","volume":"111","author":"NL Henry","year":"2008","unstructured":"Henry NL et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365\u2013372","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"5270_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-010-0757-7","volume":"120","author":"OS Din","year":"2010","unstructured":"Din OS, Dodwell D, Wakefield RJ, Coleman RE (2010) Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 120(3):525\u2013538","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"5270_CR13","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120\u20134128","journal-title":"J Clin Oncol"},{"key":"5270_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"A Buzdar","year":"2006","unstructured":"Buzdar A, Howell A, Cuzick J (2006) Arimidex, tamoxifen, alone or in combination trialists\u2019 group comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 7:633\u2013643","journal-title":"Lancet Oncol."},{"issue":"25","key":"5270_CR15","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2007.10.7573","volume":"25","author":"KD Crew","year":"2007","unstructured":"Crew KD et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877\u20133883","journal-title":"J Clin Oncol"},{"issue":"13","key":"5270_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/cncr.28016","volume":"119","author":"LD Castel","year":"2013","unstructured":"Castel LD et al (2013) Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer 119(13):2375\u20132382","journal-title":"Cancer"},{"issue":"16","key":"5270_CR17","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.24419","volume":"115","author":"JJ Mao","year":"2009","unstructured":"Mao JJ et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631\u20133639","journal-title":"Cancer"},{"issue":"12","key":"5270_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S1474-4422(16)30231-9","volume":"15","author":"L Padua","year":"2016","unstructured":"Padua L et al (2016) Carpal tunnel syndrome: clinical features, diagnosis, and management. Lancet Neurol. 15(12):1273\u20131284","journal-title":"Lancet Neurol."},{"issue":"4","key":"5270_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3816\/CBC.2008.n.043","volume":"8","author":"T Nishihori","year":"2008","unstructured":"Nishihori T et al (2008) Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clin. Breast Cancer 8(4):362\u2013365","journal-title":"Clin. Breast Cancer"},{"issue":"9561","key":"5270_CR20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC et al (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133\u00a0years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559\u2013570","journal-title":"Lancet"},{"issue":"8","key":"5270_CR21","first-page":"1654","volume":"53","author":"L Padua","year":"1999","unstructured":"Padua L, Padua R, Lo Monaco M, Aprile I, Tonali P (1999) Multiperspective assessment of carpal tunnel syndrome: a multicenter study. Italian CTS Study Group. Neurology 53(8):1654\u20131659","journal-title":"Italian CTS Study Group. Neurology"},{"issue":"12","key":"5270_CR22","first-page":"993","volume":"94","author":"J Wipperman","year":"2016","unstructured":"Wipperman J, Goerl K (2016) Carpal tunnel syndrome: diagnosis and management. Am Fam Physician 94(12):993\u2013999","journal-title":"Am Fam Physician"},{"issue":"3","key":"5270_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ocl.2016.03.005","volume":"47","author":"JD Gillig","year":"2016","unstructured":"Gillig JD, White SD, Rachel JN (2016) Acute carpal tunnel Syndrome: a review of current literature. Orthop Clin North Am 47(3):599\u2013607","journal-title":"Orthop Clin North Am"},{"issue":"5","key":"5270_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0266-7681(03)00151-7","volume":"28","author":"V Kamath","year":"2003","unstructured":"Kamath V, Stothard J (2003) A clinical questionnaire for the diagnosis of carpal tunnel syndrome. J. Hand Surg. 28(5):455\u2013459","journal-title":"J. Hand Surg."},{"issue":"1","key":"5270_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-006-9394-6","volume":"104","author":"L Morales","year":"2007","unstructured":"Morales L et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87\u201391","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5270_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.2015.63.4972","volume":"34","author":"F Spagnolo","year":"2016","unstructured":"Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J (2016) Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II prevention trial. J Clin Oncol 34(2):139\u2013143","journal-title":"J Clin Oncol"},{"issue":"24","key":"5270_CR27","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2014.55.8361","volume":"32","author":"JH Rowland","year":"2014","unstructured":"Rowland JH, Bellizzi KM (2014) Cancer survivorship issues: life after treatment and implications for an aging population. J Clin Oncol 32(24):2662\u20132668","journal-title":"J Clin Oncol"},{"issue":"30","key":"5270_CR28","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1200\/JCO.2009.22.0236","volume":"27","author":"I Sestak","year":"2009","unstructured":"Sestak I, Sapunar F, Cuzick J (2009) Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27(30):4961\u20134965","journal-title":"J Clin Oncol"},{"issue":"12","key":"5270_CR29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/obr.12324","volume":"16","author":"R Shiri","year":"2015","unstructured":"Shiri R, Pourmemari MH, Falah-Hassani K, Viikari-Juntura E (2015) The effect of excess body mass on the risk of carpal tunnel syndrome: a meta-analysis of 58 studies. Obes Rev 16(12):1094\u20131104","journal-title":"Obes Rev"},{"issue":"4","key":"5270_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1470-2045(11)70345-X","volume":"13","author":"PE Liedke","year":"2012","unstructured":"Liedke PE, Goss PE (2012) Aromatase inhibitors and musculoskeletal adverse events. Lancet Oncol. 13(4):333\u2013334","journal-title":"Lancet Oncol."},{"key":"5270_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","author":"HS Vasiliadis","year":"2014","unstructured":"Vasiliadis HS, Georgoulas P, Shrier I, Salanti G, Scholten RJPM (2014) Endoscopic release for carpal tunnel syndrome. Rev Cochrane Database Syst. \n                    https:\/\/doi.org\/10.1002\/14651858","journal-title":"Rev Cochrane Database Syst"},{"issue":"4","key":"5270_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(11)70328-X","volume":"13","author":"JSD Mieog","year":"2012","unstructured":"Mieog JSD, Morden JP, Bliss JM, Coombes RC, van de Velde CJH, IES Steering Committee (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3\u00a0years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13(4):420\u2013432","journal-title":"Lancet Oncol"},{"issue":"1","key":"5270_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/tbj.12202","volume":"20","author":"JC Brown","year":"2014","unstructured":"Brown JC, Mao JJ, Stricker C, Hwang W-T, Tan K-S, Schmitz KH (2014) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J. 20(1):22\u201328","journal-title":"Breast J."},{"issue":"4","key":"5270_CR34","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/ecc.12155","volume":"23","author":"CA DeNysschen","year":"2014","unstructured":"DeNysschen CA, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O\u2019Connor T (2014) Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. Eur. J. Cancer Care (Engl.) 23(4):493\u2013501","journal-title":"Eur. J. Cancer Care (Engl.)"},{"issue":"19","key":"5270_CR35","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1200\/JCO.2007.15.4005","volume":"26","author":"L Morales","year":"2008","unstructured":"Morales L et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147\u20133152","journal-title":"J Clin Oncol"},{"issue":"2","key":"5270_CR36","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/annonc\/mds290","volume":"24","author":"A Lintermans","year":"2013","unstructured":"Lintermans A et al (2013) Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol 24(2):350\u2013355","journal-title":"Ann Oncol"},{"issue":"18","key":"5270_CR37","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1002\/cncr.25385","volume":"116","author":"NL Henry","year":"2010","unstructured":"Henry NL et al (2010) A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116(18):4360\u20134367","journal-title":"Cancer"},{"issue":"8","key":"5270_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.steroids.2011.02.034","volume":"76","author":"A Lintermans","year":"2011","unstructured":"Lintermans A, Neven P (2011) Pharmacology of arthralgia with estrogen deprivation. Steroids 76(8):781\u2013785","journal-title":"Steroids"},{"issue":"31","key":"5270_CR39","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.1200\/JCO.2010.28.5064","volume":"28","author":"JN Ingle","year":"2010","unstructured":"Ingle JN et al (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28(31):4674\u20134682","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05270-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05270-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T23:19:09Z","timestamp":1589066349000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05270-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["5270"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05270-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2019,5,11]]},"assertion":[{"value":"23 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JS, ALB, RV, GR, JG, SCJ, ZZ, JH, AN, AMS, and KT declare that they have no conflict of interest. AB has received grants from Biothernostics Inc, Immunomedics, Novartis, Genentech\/Roche, Merck, Radius Health, Spectrum Pharma, Innocrin, and Mersana Pharmaceuticals; consultant to Immunomedics, Novartis, Genentech\/Roche, Merck, Radius Health, Spectrum Pharma, Taiho Pharma, Biothernostics Inc and Sanofi. GR has received grants from AxoGen and Allergan; patents US PCT\/US2009\/000,887, Europe 09710338.6-1222, Brazil PI0908087-2, licensed to Aegeria Soft Tissue; patent US 6\u2009+\u20092\/119,047 issued to Sonavex. DFH has received grants from Pfizer, Novartis and Astra Zeneca; Stock in Oncimmune LLC and Inbiomotion; Consultant\/advisory panels with Cepheid, Freenome Inc, Artiman Ventures (CellWorks), CVS Caremark, Agendia Inc.; Sponsored Research with Merrimack Pharmaceuticals, Eli Lilly, Menarini Silicon BioSystems, Puma Biotechnology, Pfizer, Astra Zeneca; Patents US 8790, 878 B2 licensed to Menarini Silicon BioSystems. NLH has received grants from NIH, Pfizer, Novartis, AbbVie, H3 Biomedicine, and Innocrin Pharmaceuticals. VS has received grants from Abbvie, Biocept, Pfizer, Novartis, Medimmune, and Puma Biotechnology; data safety monitoring board for Immunomedics; consultant to Iridium Therapeutics, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}